Latest Conference Articles

BTX-1188 Demonstrates Safety Benefits, Enters Phase 1 Trials in AML and Solid Tumors

BTX-1188, a first-in-class oral molecular glue, is undergoing investigation in phase 1 clinical trials in patients with solid tumors or acute myeloid leukemia, after preclinical trials supported its potential safety benefits in this population and demonstrated its high sensitivity in Myc-driven cancer cell lines.

Epcoritamab Plus R-CHOP Shows Efficacy and Tolerability as First-Line Treatment for High-Risk DLBCL

The addition of subcutaneous epcoritamab to standard-of-care R-CHOP demonstrated clinically meaningful response in the first-line treatment of patients with high-risk diffuse large B-cell lymphoma according to updated results of a single-arm of the EPCORE NHL-2 trial.

Magrolimab Plus Azacitidine Elicits Manageable Anemia in HR-MDS

Magrolimab plus azacitidine, at priming and maintenance doses, enables manageable anemia in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, according to results from a prospective phase 1 study (NCT03248479).

Hyper-CVAD Plus Sequential Blinatumomab With or Without Inotuzumab Elicits Clinical Benefit in Ph-Negative B-Cell ALL

Sequential administration of blinatumomab with or without inotuzumab following hyper-CVAD elicited high rates of minimal residual disease negativity and a durable overall survival benefit among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic lymphoma.

Addition of Ivosidenib to Azacitidine Improves Outcomes in Newly Diagnosed IDH1-Mutant AML

The combination of ivosidenib and azacitidine elicited a clinically meaningful benefit across end points compared with azacitidine alone among patients with newly diagnosed IDH1-mutant acute myeloid leukemia who were ineligible for intensive induction chemotherapy.

Glofitamab Demonstrates Durable Response in Heavily Pretreated Large B-Cell Lymphoma

Glofitamab elicited an objective response rate of 51.6% when administered for a fixed duration among patients with patients with heavily pretreated, highly refractory large B-cell lymphoma, regardless of prior CAR T-cell therapy exposure, according to findings from a phase 2 expansion study.

Sacituzumab Govitecan Demonstrates Significant Clinical Benefit in HR+/HER2- Metastatic Breast Cancer

Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative breast cancer with endocrine therapy resistance, reducing the risk of disease progression by 34% vs standard chemotherapy, according to results of the phase 3 TROPiCS-02 trial.

Pacritinib Offers Safe and Tolerable Treatment Option for Patients With Myelofibrosis

Treatment with pacritinib demonstrated a comparable safety profile to best available therapies for the treatment of patients with myelofibrosis.

Adjuvant Everolimus Displays RFS Benefit in Very High-Risk RCC

Adjuvant everolimus significantly improved recurrence-free survival when compared with placebo in patients with very high-risk renal cell carcinoma.

Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial Cancer

Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.

Single-Agent Cabozantinib Stalls as Maintenance Therapy in Advanced Urothelial Cancer

Results of the ATLANTIS study do not support further investigation of cabozantinib alone as a maintenance therapy after platinum-based chemotherapy in unselected patients with advanced urothelial cancer.

Avasopasem Reduces Severe Oral Mucositis In Patients Receiving Chemoradiotherapy for Advanced Head and Neck Cancer

Avasopasem significantly reduced severe oral mucositis across all intensity-modulated radiotherapy landmarks in patients with locally advanced, nonmetastatic head and neck cancer.

Dr. Spira on the Potential Role of Adagrasib in NSCLC

Alexander I. Spira, MD, PhD, FACP, discusses the adagrasib in patients with non–small cell lung cancer in the phase 2 KRYSTAL-1 trial.

Frontline Brentuximab Vedotin Plus Chemotherapy Improves 6-Year Survival in Hodgkin Lymphoma

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine demonstrated a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, with a manageable safety profile consistent with prior findings in patients with previously untreated stage III/IV classical Hodgkin lymphoma.

CLN-081 Produces Antitumor Activity With Acceptable Safety in Heavily Pretreated EGFR Exon 20 Insertion+ NSCLC

The selective EGFR inhibitor CLN-081 elicited objective responses in heavily pretreated patients with non–small cell lung cancer with EGFR exon 20 insertions and was found to have an acceptable toxicity profile, according to data from the phase 1/2a CLN-081-001 trial.

Dr. Wang on the Results of the Phase 3 SHINE Study in MCL

Michael Wang, MD, discusses the results of the phase 3 SHINE trial in older patients with mantle cell lymphoma.

Superior Survival Benefit With Ramucirumab Plus Pembrolizumab Observed in ICI-Resistant NSCLC

The addition of ramucirumab to pembrolizumab elicited significant response among patients with advanced non–small cell lung cancer who experienced disease progression following treatment with PD-1/PD-L1 inhibitors and platinum-based doublet chemotherapy.

Adagrasib Elicits Deep and Durable Responses in Pretreated KRAS G12C–Mutant NSCLC

Adagrasib led to early onset and deep responses translating to encouraging survival as a single agent in previously treated patients with KRAS G12C–mutated non–small cell lung cancer, according to results from cohort A of the phase 1/2 KRYSTAL-1 trial.

Sugemalimab Shows Promise for Natural Killer/T-cell Lymphoma

Treatment with the anti–PD-L1 IgG4 antibody sugemalimab resulted in a response for nearly half of patients and a complete response in one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.

Ibrutinib Plus Bendamustine and Rituximab Shows PFS Benefit in Older Patients with MCL

Ibrutinib in combination with bendamustine and rituximab with rituximab maintenance elicited a significant improvement in progression-free survival compared with standard chemoimmunotherapy in older patients with mantle cell lymphoma.

Uliledlimab/Toripalimab Combo Demonstrates Efficacy and Safety in Advanced NSCLC

Uliledlimab in combination with toripalimab generated notable response rates in patients with advanced non–small cell lung cancer who were previously ineligible to receive standard-of-care treatment.

Black Patients Less Likely to Participate on Clinical Trials in Breast Cancer

Black patients were less likely to be included in clinical trials that investigate newer treatments for metastatic breast cancer, despite having the highest death rate and shortest survival outcomes when compared with other racial and ethnic groups in the United States.

Disparities Remain Regarding Access to Telehealth

Disparities in access to telehealth for cancer care were seen across more than 20 tumor types, according to study findings that were presented during a press briefing ahead of the 2022 ASCO Annual Meeting.

Hispanic Ethnicity Associated With Poorer OS in Pediatric Neuroblastoma

Non-White Hispanic children and those with public insurance care in a clinical trial for high-risk neuroblastoma had inferior overall survival rates compared with other children.

Frontline Encorafenib/Cetuximab Plus or Minus Chemo Is Under Evaluation for BRAF V600E–Mutant mCRC

The safety and efficacy of encorafenib plus cetuximab with or without standard-of-care chemotherapy will be compared with that of chemotherapy alone in patients with BRAF V600E–mutated metastatic colorectal cancer as part of the phase 3 BREAKWATER trial.

Frontline Datopotamab Deruxtecan/Durvalumab Combo Elicits Encouraging Responses in TNBC

The combination of the TROP2-directed antibody-drug conjugate datopotamab deruxtecan and durvalumab showcased early activity with acceptable safety when used as first-line treatment in patients with locally advanced or metastatic triple-negative breast cancer, according to data from the phase 1b/2 BEGONIA trial.

Tislelizumab Plus Nab-Paclitaxel Yields Preliminary Efficacy in NMBIC

The combination of tislelizumab plus nab-paclitaxel demonstrated benefit and a tolerable safety profile in patients with high-risk non–muscle invasive bladder cancer.

Sabizabulin Yields Encouraging rPFS, Tolerable Toxicity Profile in Previously Treated mCRPC

The utilization of sabizabulin in patients with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting therapy yielded significant and durable objective tumor responses, according to results of a phase 1b/2 trial (NCT03752099).

Immunotherapy Plus Nadofaragene Firadenovec Could Display Synergistic Activity in NMIBC

Nadofaragene firadenovec combined with immune checkpoint inhibitors such as pembrolizumab may play a synergistic role in the treatment of patients with Bacillus Calmette–Guérin-unresponsive non–muscle invasive bladder cancer.

Antegrade Administration of Mitomycin Gel Provides Safe, Effective Approach in Upper Tract Urothelial Carcinoma

Data from a retrospective analysis demonstrated that mitomycin gel was safe and effective when administered using an antegrade approach in real-world populations of patients with low-grade upper tract urothelial cancer.